rofecoxib has been researched along with Allergy, Drug in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To classify patients with a history of aspirin-induced urticaria as cross-reactors or single-drug reactors by oral challenges with another strong COX-1 inhibitor, namely, ketoprofen." | 9.12 | Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. ( Asero, R, 2006) |
| "Sixty patients with asthma underwent doubleblinded, placebo-controlled oral challenges with rofecoxib (12." | 9.09 | Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. ( Simon, RA; Stevenson, DD, 2001) |
| "To review the safety of cyclooxygenase-2 (COX-2) inhibitors in asthma patients with aspirin hypersensitivity." | 8.82 | Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. ( Fernández, C; West, PM, 2003) |
| " Clinical data show that mixed COX-1/COX-2 inhibitors such as aspirin, but not COX-2 selective inhibitors such as rofecoxib, induce bronchoconstriction and asthma in sensitive individuals." | 7.74 | COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. ( Harrington, LS; Lucas, R; McMaster, SK; Mitchell, JA; Moreno, L; Scadding, G; Warner, TD, 2008) |
| "To classify patients with a history of aspirin-induced urticaria as cross-reactors or single-drug reactors by oral challenges with another strong COX-1 inhibitor, namely, ketoprofen." | 5.12 | Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. ( Asero, R, 2006) |
| " Three subjects with multiple-drug induced urticaria complained of a generalized reaction after challenge (Two due to celecoxib and one due to meloxicam)." | 5.11 | Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. ( Antonicelli, L; Bilò, MB; Bonadonna, P; Crivellaro, MA; Dama, AR; Schiappoli, M; Senna, G, 2004) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by progressive sinusitis, nasal polyposis, and asthma that begins and continues in the absence of exposure to aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)." | 5.11 | Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. ( Simon, RA; Stevenson, DD; Woessner, KM, 2004) |
| "To compare the clinical tolerance to rofecoxib and valdecoxib in patients who previously developed urticaria and angioedema while taking classic NSAIDs." | 5.11 | Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. ( Caballero-Fonseca, F; Capriles-Hulett, A; Sánchez-Borges, M, 2005) |
| "Sixty patients with asthma underwent doubleblinded, placebo-controlled oral challenges with rofecoxib (12." | 5.09 | Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. ( Simon, RA; Stevenson, DD, 2001) |
| "To review the safety of cyclooxygenase-2 (COX-2) inhibitors in asthma patients with aspirin hypersensitivity." | 4.82 | Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. ( Fernández, C; West, PM, 2003) |
| " Clinical data show that mixed COX-1/COX-2 inhibitors such as aspirin, but not COX-2 selective inhibitors such as rofecoxib, induce bronchoconstriction and asthma in sensitive individuals." | 3.74 | COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. ( Harrington, LS; Lucas, R; McMaster, SK; Mitchell, JA; Moreno, L; Scadding, G; Warner, TD, 2008) |
| "Rofecoxib appears to be a safe alternative drug among atopic individuals, antibiotic-hypersensitive individuals, and individuals who experienced adverse cutaneous reactions to more than 1 class of NSAIDs, but it is less safe among chronic urticaria patients." | 3.73 | Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. ( Colanardi, MC; Ferrannini, A; Nettis, E; Tursi, A, 2005) |
| " One hundred twenty-seven subjects with history of adverse reaction to ASA/NSAIDs received oral challenges with nimesulide, 61 subjects were challenged with meloxicam, 51 subjects were challenged with rofecoxib, and 37 subjects were challenged with all three drugs." | 2.71 | Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. ( Bavbek, S; Celik, G; Misirligil, Z; Mungan, D; Ozer, F, 2004) |
| "Controlled oral challenge with nonsteroidal anti-inflammatory drugs (NSAIDs) is the only definite way to detect safe NSAIDs in patients with NSAID-induced anaphylactoid reactions." | 2.71 | Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. ( Conde, J; Delgado, J; Florido, JF; López-Pascual, E; Nieto, MA; Ortega, N; Quiralte, J; Sáenz de San Pedro, B, 2004) |
| " A tolerance observed to this drug during SBPCOCs will indicate a safe alternative in this patient-group." | 2.70 | Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. ( Florido, JJ; Quiralte, J; Sáenz de San Pedro, B, 2002) |
| "Rofecoxib is a safe alternative in subjects with previous adverse cutaneous reaction to NSAIDs." | 2.70 | Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. ( Barbagallo, M; Biasi, D; Corrocher, R; Di Lorenzo, G; Pacor, ML, 2002) |
| "Rofecoxib can be used as a safe alternative drug for ASA/NSAID intolerant patients." | 1.33 | Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients. ( Bavbek, S; Celik, G; Misirligil, Z; Pasaoglu, G, 2006) |
| "Rofecoxib is a novel NSAID which selectively inhibits prostaglandin endoperoxide H synthase-2 and has no effect on prostaglandin endoperoxide H synthase-1." | 1.31 | Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. ( Di, PR; Ferrannini, A; Nettis, E; Tursi, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harrington, LS | 1 |
| Lucas, R | 1 |
| McMaster, SK | 1 |
| Moreno, L | 1 |
| Scadding, G | 1 |
| Warner, TD | 1 |
| Mitchell, JA | 1 |
| Quiralte, J | 2 |
| Sáenz de San Pedro, B | 2 |
| Florido, JJ | 1 |
| Valero, A | 1 |
| Baltasar, M | 1 |
| Enrique, E | 2 |
| Pau, L | 1 |
| Dordal, MT | 1 |
| Cisteró, A | 1 |
| Martí, E | 1 |
| Picado, C | 1 |
| Kruse, R | 1 |
| Ruzicka, T | 1 |
| Grewe, M | 1 |
| Verrico, MM | 1 |
| Weber, RJ | 1 |
| McKaveney, TP | 1 |
| Ansani, NT | 1 |
| Towers, AL | 1 |
| West, PM | 1 |
| Fernández, C | 1 |
| Perrone, MR | 1 |
| Artesani, MC | 1 |
| Viola, M | 1 |
| Gaeta, F | 1 |
| Caringi, M | 1 |
| Quaratino, D | 1 |
| Romano, A | 1 |
| Bavbek, S | 2 |
| Celik, G | 2 |
| Ozer, F | 1 |
| Mungan, D | 1 |
| Misirligil, Z | 2 |
| Senna, G | 1 |
| Bilò, MB | 1 |
| Antonicelli, L | 1 |
| Schiappoli, M | 1 |
| Crivellaro, MA | 1 |
| Bonadonna, P | 1 |
| Dama, AR | 1 |
| Matucci, A | 1 |
| Parronchi, P | 1 |
| Vultaggio, A | 1 |
| Rossi, O | 1 |
| Brugnolo, F | 1 |
| Maggi, E | 1 |
| Romagnani, S | 1 |
| Woessner, KM | 1 |
| Simon, RA | 2 |
| Stevenson, DD | 2 |
| Delgado, J | 1 |
| López-Pascual, E | 1 |
| Nieto, MA | 1 |
| Ortega, N | 1 |
| Florido, JF | 1 |
| Conde, J | 1 |
| Nettis, E | 2 |
| Colanardi, MC | 1 |
| Ferrannini, A | 2 |
| Tursi, A | 2 |
| Sánchez-Borges, M | 1 |
| Caballero-Fonseca, F | 1 |
| Capriles-Hulett, A | 1 |
| Pasaoglu, G | 1 |
| Asero, R | 1 |
| Cisteró-Bahíma, A | 1 |
| San Miguel-Moncín, MM | 1 |
| Alonso, R | 1 |
| Zollner, TM | 1 |
| Ahlbach, S | 1 |
| Kaufmann, R | 1 |
| Boehncke, WH | 1 |
| Hinrichs, R | 1 |
| Ritzkowsky, A | 1 |
| Hunzelmann, N | 1 |
| Krieg, T | 1 |
| Scharffetter-Kochanek, K | 1 |
| Berges-Gimeno, MP | 1 |
| Camacho-Garrido, E | 1 |
| García-Rodriguez, RM | 1 |
| Alfaya, T | 1 |
| Martín García, C | 1 |
| Hinojosa, M | 1 |
| Di, PR | 1 |
| Pacor, ML | 1 |
| Di Lorenzo, G | 1 |
| Biasi, D | 1 |
| Barbagallo, M | 1 |
| Corrocher, R | 1 |
1 review available for rofecoxib and Allergy, Drug
| Article | Year |
|---|---|
Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Cyclooxygenase 2; Drug Hypersen | 2003 |
11 trials available for rofecoxib and Allergy, Drug
| Article | Year |
|---|---|
Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2002 |
Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase | 2003 |
Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase In | 2004 |
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celec | 2004 |
Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cross Reactions; Cyclooxygenase Inhibitors | 2004 |
Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Celecoxib; Cyclooxyge | 2004 |
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Cyclooxygenase Inhibitors | 2005 |
Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
Topics: Acetaminophen; Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroida | 2006 |
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Er | 2001 |
Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cross Reactions; Cyclooxygenase Inhibitors | 2001 |
Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Double-Blind Met | 2002 |
11 other studies available for rofecoxib and Allergy, Drug
| Article | Year |
|---|---|
COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Animals; Aspirin; | 2008 |
NSAID-sensitive patients tolerate rofecoxib.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Controlled Cli | 2002 |
Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Hypersensitivity | 2003 |
Adverse Drug Events Involving COX-2 Inhibitors.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2003 |
Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross Reactions; Cyclooxygenase In | 2004 |
Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Cyclooxygenase Inhibitors; Drug Hypers | 2005 |
Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Drug Hypersens | 2006 |
Rofecoxib should be tried in NSAID hypersensitivity.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Fe | 2000 |
Rofecoxib as an alternative in aspirin hypersensitivity.
Topics: Adult; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Hyper | 2001 |
Rofecoxib safe in NSAID hypersensitivity.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Hypersensitivity; Female; Hum | 2001 |
Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Drug Hypersensit | 2002 |